France's Ipsen halted a late-stage study of a four-month formulation of triptorelin after the data didn't support sustained blood levels of the therapy. Researchers are searching for a new formulation to take the place of the three-month formulation of Decapeptyl when that patent expires. Company officials say they still expect to develop a new formulation in time.
- read the AFX report on the trial